| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3d7e466c44c7b54e2a48e4bf62665ef |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 |
| filingDate |
2018-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef72c2e2d082165a7d20717dce02ccbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85a42dfa9fb83689d73b7e80dc72e23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c8492776efe70185437d32494288820
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e25202f66d9ea62ed751f8ed0cbd152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e53119f11b1f5abdffdd32928fc5b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bca3d2831a8a7a476211de264a7f4727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b40bf9adf41026311286a44a82bc4b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e69527052eadaee40e1ecf4b6328780e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df575c1972c5683aeaaf523c7a00a37f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc8f42614aad0d1fdc86973bc84f8738
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d3ef1ae38579f08f4fc33fb2e55bc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954037b796ec05fa022c1ac18d7bac35 |
| publicationDate |
2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109498630-A |
| titleOfInvention |
Containing progestational hormone product and its inhibiting the application in vascular endothelial growth factor expression |
| abstract |
The invention belongs to biomedicine fields, and the invention discloses the applications inhibited in VEGF-C expression that progesterone receptor cis-acting elements is mediated in progestational hormone.Inhibit the expression of vascular endothelial growth factor C by combining the activity of the promoter region of vascular endothelial growth factor and/or the progesterone receptor functional element of 5 ' UTR regions to realize.The nucleotide sequence of the promoter of vascular endothelial growth factor C and 5 ' UTR and its PREs sequence contained are as shown in sequence 1 in sequence table.The present invention has important application value. |
| priorityDate |
2018-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |